Join to View Full Profile
801 Ostrum StBethlehem, PA 18015
Phone+1 484-503-4673
Fax+1 484-503-4501
Dr. Arriaga is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 1994 - 1997
Cayetano Heredia UniversityClass of 1991
Certifications & Licensure
AZ State Medical License 1997 - Present
PA State Medical License 2023 - 2026
NJ State Medical License 2024 - 2025
TX State Medical License 2006 - 2025
MI State Medical License 1996 - 2000
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine Start of enrollment: 2009 Mar 02
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Start of enrollment: 2010 Oct 15
Publications & Presentations
PubMed
- 1 citationsBaseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.Helen Gogas, Shruthi Ravimohan, Antara Datta, Aparna Chhibber, Eva Muñoz Couselo
NPJ Precision Oncology. 2024-07-19 - 18 citationsBempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V Long, Paolo A Ascierto
Journal of Clinical Oncology. 2023-10-20 - 5 citationsPhase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer.Raquibul Hannan, Michael J Dohopolski, Laurentiu M Pop, Samantha Mannala, Lori Watumull
Biomedicines. 2022-06-15
Journal Articles
- Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the in Vitro Integrity of T-cells from Cancer PatientsKevin Courtney, Yull Arriaga, Barbara Haley, John C Mansour, Ponciano D Cruz, David Harker, Farshid Araghizadeh, Clinical Cancer Research
Press Mentions
What Is Melanoma?July 8th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
